Safety and Efficacy of Sorafenib in Renal Cell Carcinoma

Julien Edeline; Elodie Vaul�on; Nathalie Rioux-Leclercq; Christophe Perrin; C�cile Vigneau; Karim Bensalah; Brigitte Laguerre

JOURNAL

Cancer Growth and Metastasis

Safety and Efficacy of Sorafenib in Renal Cell Carcinoma

Julien Edeline, Elodie Vauléon, Nathalie Rioux-Leclercq, Christophe Perrin, Cécile Vigneau, Karim Bensalah and Brigitte Laguerre

Cancer Growth and Metastasis 2012:5 35-47

Review

Published on 12 Nov 2012

DOI: 10.4137/CGM.S7526

Further metadata provided in PDF

Download Article PDF

Sign up for email alerts to receive notifications of new articles published in Cancer Growth and Metastasis

Abstract and Sharing
Article Metrics
Discuss

Abstract

This article reviews data on sorafenib use in renal cell carcinoma. Mechanisms of actions and pharmacokinetics are briefly described. Major clinical trials are presented, summarizing efficacy and safety of sorafenib. Its place in current treatment of renal cell carcinoma is discussed. Sorafenib is likely to remain one of the mainstays of RCC treatment in coming years.

Downloads

PDF (1.13 MB PDF FORMAT)

RIS citation (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation (BIBDESK, LATEX)

What Your Colleagues Say About Cancer Growth and Metastasis

My experience with the review stages and manuscript processing in Cancer Growth and Metastasis has been of excellence. The fine balance of times utilized for proper scientific assessment of the material and quality control is greatly commended.

Dr Carlos Telleria (Sanford School of Medicine of The University of South Dakota, Vermillion, SD, USA)

More Testimonials